- Home
- VTYX vs PFLT Comparison
VTYX vs PFLT Comparison
Compare VTYX & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VTYX | PFLT |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.9M | 899.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VTYX | PFLT |
|---|---|---|
| Price | $13.95 | $8.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $13.50 | $10.67 |
| AVG Volume (30 Days) | ★ 2.3M | 1.2M |
| Earning Date | 02-27-2026 | 02-09-2026 |
| Dividend Yield | N/A | ★ 14.25% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.36 |
| Revenue | N/A | ★ $264,507,000.00 |
| Revenue This Year | N/A | $11.75 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $24.28 |
| Revenue Growth | N/A | ★ 22.80 |
| 52 Week Low | $0.78 | $8.40 |
| 52 Week High | $25.00 | $11.46 |
Technical Indicators
Market Signals| Indicator | VTYX | PFLT |
|---|---|---|
| Relative Strength Index (RSI) | 72.03 | 26.56 |
| Support Level | $13.91 | $9.27 |
| Resistance Level | $13.97 | $9.52 |
| Average True Range (ATR) | 0.04 | 0.20 |
| MACD | -0.18 | -0.10 |
| Stochastic Oscillator | 54.55 | 10.59 |
Price Performance
Historical ComparisonAbout VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate both current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generates revenue in the form of interest income on the debt securities and dividends.